Bullous Pemphigoid Associated With Pembrolizumab Therapy for Non-Small-Cell Lung Cancer: A Case Report

Pembrolizumab is an immune checkpoint inhibitor being increasingly used as immunotherapy for a multitude of cancers. With the increasing use of these agents, various immune-related adverse events are being recognized. Lichenoid reaction, pruritus, and eczema are well-established cutaneous side effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Chatterjee, Tulika, Rashid, Thomas F, Syed, Salman B, Roy, Moni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Dermatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8890109/
https://www.ncbi.nlm.nih.gov/pubmed/35251840
http://dx.doi.org/10.7759/cureus.21770

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8890109/
https://www.ncbi.nlm.nih.gov/pubmed/35251840
http://dx.doi.org/10.7759/cureus.21770

Ejemplares similares